Targeting the PI3K Pathway in HR+/HER2- MBC

Download this slideset to review the latest clinical data on the evolving role of mTOR, PIK3, and ALK inhibitors in the treatment of HR+/HER2- metastatic breast cancer.
Sara Hurvitz, MD, FACP
Format: Microsoft PowerPoint (.ppt)
File Size: 1.05 MB
Released: May 31, 2019


Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

This activity is supported by educational grants from
Novartis Pharmaceuticals Corporation

For further information concerning Lilly grant funding, visit

Related Content

Expert commentary from Hope Rugo, MD, on integrating atezolizumab into treatment plans for metastatic TNBC provided by Clinical Care Options (CCO)

Hope S. Rugo, MD Released: April 2, 2020

Expert commentary from Clinical Care Options (CCO) on managing potential immune-related adverse events associated with atezolizumab treatment for metastatic TNBC

person default Sarah Donahue, MPH, NP Released: March 16, 2020

Review key data in the treatment of breast cancer from SABCS 2019 with this set of CME-certified expert commentaries from CCO

Sara Hurvitz, MD, FACP Joyce O'Shaughnessy, MD Sara Tolaney, MD, MPH Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: March 2, 2020 Expired: March 1, 2021

Joyce O’Shaughnessy, MD, provides insights on key studies in HR-positive/HER2-negative breast cancer from 2019 SABCS for Clinical Care Options (CCO)

Joyce O'Shaughnessy, MD Released: January 31, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the,, and Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?